Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 8Breast Neoplasms 6Malnutrition 5Stomach Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Pancreatic Neoplasms 3Lung Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Lymphoma 2Locally Advanced Head and Neck Carcinoma 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Cachexia 2Biliary Tract Neoplasms 2Wilms Tumor 1Surgery--Complications 1Sarcoma 1Prostatic Intraepithelial Neoplasia 1Peripheral Nervous System Diseases 1Peptic Ulcer 1Osteoporosis 1Nutrition Related Cancer 1Neurotoxicity Syndromes 1Neurofibromatosis 1 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1

Interventions

Ribavirin 4ledipasvir 3peginterferon alfa-2a 2ledipasvir, sofosbuvir drug combination 2Sofosbuvir 2sofosbuvir-velpatasvir drug combination 1daclatasvir 1Viusid 1Simeprevir 1Metformin 1Introns 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis C, Chronic × Dietary Supplements × Clear all
NCT00502086 2011-02-11

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Catalysis SL

Phase 3 Completed
100 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡